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RLong-Term Survival of Patients
With Resting Obstructive
Hypertrophic Cardiomyopathy
More Questions Than Answers
We read with interest the recent paper by Ball et al. (1).
Hypertrophic cardiomyopathy (HCM) is an important topic; we
commend the authors for analyzing the largest cohort with resting
obstructive HCM. However, we question some key points.
First, significant differences exist between the conservative
group (CG) and the invasive group (IG). The CG was older (CG
age 57 16 years vs. IG age 47 15 years; p 0.0001), had more
women (50% vs. 40%, respectively; p  0.0006), and had a higher
burden of major comorbidities than the IG (18.3% vs. 8.4%,
respectively; p  0.0002). Although age and sex were covariates in
the multivariable analysis (MVA), the interaction of age and sex
was not evaluated. Therefore, it cannot be determined whether the
difference in follow-up year survival results from differences in age,
sex, or a combination thereof. Moreover, for unspecified reasons,
the MVA dichotomized age at 50 years. Based on the age
distributions, it appears that age older than 50 years and treatment
classification will be correlated, as approximately 70% of the CG
was older than 50 years. Conversely, disease burden was not
included in the MVA. In a group with a higher burden of diseases
that shorten survival, shorter survival is expected. With 81 deaths
(or equivalents of death) observed, the MVA could have, by
convention, included up to 8 explanatory variables. The disease
burden should have been accounted for in the MVA because
disease burden could greatly affect the survival results.
Because of the group differences and the time-varying covariate
of follow-up years in the MVA, the use of Kaplan-Meier analysis
is inappropriate, even as a secondary analysis. We recommend
using plot-predicted values based on multivariable models. Addi-
tionally, when using Kaplan-Meier to analyze death for any reason,
as opposed to death due to HCM, it is more appropriate to analyze
overall survival as a function of age and not follow-up years. The
Kaplan-Meier analysis suggests that survival length was approxi-
mately 5 years less in the CG. The authors’ conclusion and the
overarching premise of the paper are that “patients treated inva-
sively have an overall survival advantage compared with conserva-
tively treated patients.” If age is considered, as opposed to
follow-up years, the authors’ conclusion may not be valid; Table 1
and Figure 1 in the paper by Ball et al. (1) indicate that, on average,
the CG actually lived to an older age (approximately 5 years older
than the IG).
Although the authors’ findings do demonstrate that younger
patients with resting obstructive HCM in this cohort study lived
longer during follow-up, their other conclusions are in question.
The results of the MVA, details on the methods used to select the
variables in the model, and lack of appropriate disease severityaccounting lead to weaknesses too significant to overlook. As a
result, we are not convinced that, based on the results at hand,
there is any scientific evidence that invasive therapy in the setting
of resting obstructive HCM is associated with any benefit.
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Reply
We thank Dr. Collins and colleagues for their valuable comments
on our paper (1). We would like to address the issues they raised.
First, Dr. Collins and colleagues draw attention to the fact that
we did not examine the interaction between age and sex in our
multivariable model. We decided a priori to evaluate a main effects
model only. Furthermore, other studies in the literature have also
demonstrated that age and sex are independent predictors of
long-term outcome in patients with hypertrophic cardiomyopathy
(HCM) (2,3). In addition, the authors seem to question the
rationale for our dichotomization of age at 50 years. We assert that
this age cutoff is justifiable for a few reasons. Our group previously
showed that the age 50 years group is associated with worsened
survival in patients who underwent myectomy (2). From a clinical
standpoint, this age cutoff is relevant because there are important
differences between adult patients who are younger than the age 50
versus those who are middle aged and elderly. From a statistical
standpoint, the cutoff is reasonable because the mean and median
age of presentation of the entire cohort was 51 years (and the age
older than 50 years variable used in our multivariable models was
defined as age 51 and older).
Second, Dr. Collins and colleagues raise the issue that comor-
bidities were not included in our multivariable analysis. We did
add a comorbidities variable to our analysis; although the comor-
bidities variable was significant on univariate analysis, it was not
statistically significant on multivariable analysis.
Third, Dr. Collins and colleagues state that our use of Kaplan-
Meier analysis was inappropriate. We would highlight that our
primary survival analysis was a multivariable model (with invasive
therapy treated as a time-dependent covariate) (1). The conclu-
sions of our paper were based on the multivariable analyses.
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overall and HCM-related survival in the conservative and invasive
groups. Our Kaplan-Meier analyses supported the findings of our
multivariable models. We believe that these survival curves are a
simple and acceptable method of depicting survival. In our
opinion, plot-predicted values would not provide additive infor-
mation.
In addition, Dr. Collins and colleagues suggest that our Kaplan-
Meier analyses should have used age and not follow-up time (in
years) in depicting survival. We agree that analyzing survival as a
function of age may be appropriate when examining subjects with
either a congenital disorder or with a similar age at onset of the
condition of interest. However, in our study, the age at presenta-
tion to our institution spanned 8 decades (with an average age of
51  16 years), which reflects the heterogeneity of patients in this
cohort. Therefore, we think that plotting age (instead of the
follow-up time) in the Kaplan-Meier survival curves would be
completely noninformative.
We thank Dr. Collins and colleagues for their letter. However,
we believe that the conclusions of our study on the survival of
patients with resting obstructive HCM are valid and will assist
physicians managing patients with this challenging condition.
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Severe Obesity and ST-Segment
Elevation Myocardial Infarction
The Evolving Challenge
Das et al. (1) describe the association of obesity as defined by body
mass index (BMI) with outcomes of ST-segment elevation myo-
cardial infarction (STEMI). The findings of this study need to be
taken in the light of increasing recognition that BMI may not be
a true index of body adiposity (2). This is reflected in a recent studylooking at outcomes of acute coronary syndrome, in which waist
circumference, a marker of visceral obesity, proved to be a more
important discriminator in individuals with a BMI25 kg/m2 (3).
Similarly, use of a lipid accumulation product, a relatively newer
tool for identifying obese individuals, has been shown to be a better
marker of all-cause cardiovascular mortality (4). The investigators
also raise the possibility of “normal BMI representing unmeasured
comorbidities and that overweight and mild obesity likely repre-
senting the more appropriate body mass in the post-MI setting” to
explain the increased prevalence of adverse outcomes in a normal
BMI group. Although interesting, this finding and conclusion
need to be discussed in light of the fact that a BMI30 kg/m2 has
poor sensitivity for detecting true body fat (5,6).
The most important finding of this study was the significantly
higher in-hospital mortality in patients with class III obesity.
Whether this represents an adverse effect of extreme obesity on the
disease (disease effect) or suboptimal treatment strategies (treat-
ment effect) is not clear.
From the disease effect standpoint, this study recognized less
extensive coronary artery disease in class III obesity, but these
individuals may actually have more extensive vulnerable plaque.
This remains speculation, however.
More important, treatment effect is a likely scenario. These
high-risk patients, despite similar use of conventional medications
and reperfusion strategies, may have been underdosed with car-
dioprotective drugs. For example, higher BMI subjects have lower
platelet inhibition by clopidogrel (7). In the current study, clopi-
dogrel was the most commonly used second antiplatelet agent in
addition to aspirin. Along the same lines, Sarno et al. (8) reported
a higher prevalence of stent thrombosis in obese individuals.
Although speculative, these observations make a case for more
aggressive weight-adjusted antiplatelet and other drugs in class III
obese patients with STEMI.
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